

Members Obtain Free CE Credits from JCP Articles!



Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction

September 2022 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Inclisiran increases the number of low-density lipoprotein surface receptors expressed on hepatocytes using small interfering RNA directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. This novel mechanism can reduce low-density lipoprotein by ≈50%, like reductions achieved with high-intensity statins or PCSK9-inhibiting monoclonal antibodies. Inclisiran is indicated in the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, unable to achieve target LDL concentrations with diet and maximally tolerated statin therapy. It is more expensive than PCSK9-inhibiting monoclonal antibodies and still lacks clinical evidence for the expected reduction in atherosclerotic cardiovascular disease events when added to statin therapy. Although some patients experience injection-site reactions of mild or moderate severity, current evidence suggests a strong safety profile with total and serious adverse events approximating that of placebo. The dosing protocol of inclisiran offers its biggest clinical advantage over PCSK9-inhibiting monoclonal antibodies, being administered only every 6 months after initial baseline and 3-month doses rather than every second or fourth week. Unlike PCSK9-inhibiting monoclonal antibodies, inclisiran has not yet been noted to induce neutralizing antidrug antibodies that can impact drug efficacy. Learners that complete this activity will learn about a novel therapy for the treatment of lowering of "bad" cholesterol (LDL-C) along with diet and other lipid lowering therapies.

ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-22-035-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Target Audience

Interprofessional team of Physicians, Pharmacists and PhDs.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the mechanism of action of inclisiran;
2. Contrast between the mechanisms of action between inclisiran and PCSK9 monoclonal antibody inhibitors;

3. State the approximate percent decrease in LDL-C based on ORION-9, 10 and 11 clinical studies;
4. Summarize the unique dosing recommendations for subcutaneous administration.

Requirements to Receive Credit

To receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph S. Bertino Jr, PharmD, planner for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

Planners: Joseph Ma, PharmD, planner for this educational activity, owns stocks at Amgen Inc. All of the relevant financial relationships listed for these individuals have been mitigated.

CE Reviewer: Joel Reid, MD, reviewer for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 09/01/2022

Expiration Date: 09/01/2025

Helpful Tips

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).
